2024
Advances in predicting breast cancer driver mutations: Tools for precision oncology (Review).
Hao W, Rajendran B, Cui T, Sun J, Zhao Y, Palaniyandi T, Selvam M. Advances in predicting breast cancer driver mutations: Tools for precision oncology (Review). International Journal Of Molecular Medicine 2024, 55 PMID: 39450552, PMCID: PMC11537269, DOI: 10.3892/ijmm.2024.5447.Peer-Reviewed Original ResearchConceptsDisease-free survivalBreast cancerPrecision medicine approachAvailability of high-throughput sequencingPrecision oncologyTherapeutic optionsDriver mutationsDisease-free survival of patientsCancer driver gene identificationDriver gene identificationMedicine approachHigh-throughput sequencingSurvival of patientsTargeted therapeutic optionsFraction of patientsCancer driver mutationsTargeted therapeutic approachesBreast cancer treatmentIdentification of driver mutationsBreast cancer mutationsModern era of medicineCancer-specific biomarkersGene identificationCancer DatabaseCancer mutations
2023
Role of homeobox d10 gene targeted signaling pathways in cancers
Surendran H, Palaniyandi T, Natarajan S, Hari R, Viwanathan S, Baskar G, Abdul Wahab M, Ravi M, Rajendran B. Role of homeobox d10 gene targeted signaling pathways in cancers. Pathology - Research And Practice 2023, 248: 154643. PMID: 37406379, DOI: 10.1016/j.prp.2023.154643.Peer-Reviewed Original ResearchConceptsTranscription factorsHomeobox gene familyHomeotic transcription factorsGene expression changesTumor suppressor geneD10 geneGene familyHomeobox genesCancer signalingOrgan developmentTissue homeostasisGene expressionExpression changesSignaling pathwaysCell differentiationSuppressor geneFunctional interactionGenesHOXD10 geneCancer treatment targetHOXD10Pathway dysregulationTherapeutic resistancePathwayMolecule actionInsights of Endocytosis Signaling in Health and Disease
Pathak C, Vaidya F, Waghela B, Jaiswara P, Gupta V, Kumar A, Rajendran B, Ranjan K. Insights of Endocytosis Signaling in Health and Disease. International Journal Of Molecular Sciences 2023, 24: 2971. PMID: 36769293, PMCID: PMC9918140, DOI: 10.3390/ijms24032971.Peer-Reviewed Original ResearchConceptsEndocytic machineryPlasma membraneCellular defenseFundamental cellular machinerySignal transduction modulesDifferent cellular compartmentsVital physiological processesProcess of endocytosisEndocytic proteinsIndependent endocytosisEndocytosis machineryTransduction modulesEukaryotic cellsCaveolar pathwayCellular machineryMammalian cellsEndocytic pathwayCell divisionCellular compartmentsComplex proteinsFunctional characterizationPhysiological processesMachinery resultsHuman diseasesEndocytosisIntegrated transcriptome and trajectory analysis of cutaneous T-cell lymphoma identifies putative precancer populations
Ren J, Qu R, Rahman N, Lewis J, King A, Liao X, Mirza F, Carlson K, Huang Y, Gigante S, Evans B, Rajendran B, Xu S, Wang G, Foss F, Damsky W, Kluger Y, Krishnaswamy S, Girardi M. Integrated transcriptome and trajectory analysis of cutaneous T-cell lymphoma identifies putative precancer populations. Blood Advances 2023, 7: 445-457. PMID: 35947128, PMCID: PMC9979716, DOI: 10.1182/bloodadvances.2022008168.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaMalignant CTCL cellsDiverse transcriptomic profilesT cellsSingle-cell RNACTCL cellsDevelopment of CTCLIntegrated transcriptomeT-cell receptor sequencingT cell exhaustion phenotypeCommon antigenic stimulusPeripheral blood CD4Transcriptomic profilesGene expressionT-cell lymphomaIntegrative analysisPotential therapeutic targetProliferation advantageLimited diversityBlood CD4Blood involvementMutation levelsExhaustion phenotypeWorse prognosisAntigenic stimulus
2022
Gene expressions and their significance in organoid cultures obtained from breast cancer patient-derived biopsies
Pranav P, Palaniyandi T, Baskar G, Ravi M, Rajendran B, Sivaji A, Ranganathan M. Gene expressions and their significance in organoid cultures obtained from breast cancer patient-derived biopsies. Acta Histochemica 2022, 124: 151910. PMID: 35667159, DOI: 10.1016/j.acthis.2022.151910.Peer-Reviewed Original ResearchConceptsBreast cancerOrganoid culturesGene expression changesPatient-derived biopsiesBreast cancer biopsiesExpression of ErbB2Progesterone receptor geneCancer cell linesExpression changesSuch cancersPatient biopsiesCancer biopsiesSolid tumorsBiopsyMalignant cellsCancerGene expressionMagnitude of expressionHuman cancersCancer therapyReceptor geneCell linesSuch organoidsCancer researchFunctional physiologyDevelopment of patient derived organoids for cancer drug screening applications
Baskar G, Palaniyandi T, Viswanathan S, Rajendran B, Ravi M, Sivaji A. Development of patient derived organoids for cancer drug screening applications. Acta Histochemica 2022, 124: 151895. PMID: 35486967, DOI: 10.1016/j.acthis.2022.151895.Peer-Reviewed Original ResearchConceptsPre-clinical modelsEx vivo tissue cultureDevelopment of patientsCancer researchStem cellsVivo tissue culturePatient responseAbnormal cell growthProgenitor cellsHigh-throughput drug screeningVivo propertiesOrganoidsHuman organoidsPluripotent stem cellsCell growthDrug screening applicationsDrug screeningThroughput drug screeningEmbryonic stem cellsTissueCellsTissue cultureEffective recapitulationPatientsClinic
2021
Molecular landscape and subtype-specific therapeutic response of nasopharyngeal carcinoma revealed by integrative pharmacogenomics
Ding R, Chen P, Rajendran B, Lyu X, Wang H, Bao J, Zeng J, Hao W, Sun H, Wong A, Valecha M, Yang E, Su S, Choi T, Liu S, Chan K, Yang L, Wu J, Miao K, Chen Q, Shim J, Xu X, Deng C. Molecular landscape and subtype-specific therapeutic response of nasopharyngeal carcinoma revealed by integrative pharmacogenomics. Nature Communications 2021, 12: 3046. PMID: 34031426, PMCID: PMC8144567, DOI: 10.1038/s41467-021-23379-3.Peer-Reviewed Original ResearchConceptsSarcomatoid carcinomaEpithelial-mesenchymal transitionNasopharyngeal carcinomaCarcinoma subtypesNeck cancer typesPatient-derived organoidCRT regimensDistinct molecular featuresMalignant headHigh morbidityTreatment regimensTherapeutic responseEC subtypesPathogenic mechanismsDrug responsivenessEGFR inhibitorsNPC subtypesCancer typesSubtypesCarcinomaPrecision oncologyDrug testsMolecular landscapeRegimensMicrotubule inhibitorsAccelerating precision anti-cancer therapy by time-lapse and label-free 3D tumor slice culture platform
Xing F, Liu Y, Huang S, Lyu X, Su S, Chan U, Wu P, Yan Y, Ai N, Li J, Zhao M, Rajendran B, Liu J, Shao F, Sun H, Choi T, Zhu W, Luo G, Liu S, Xu D, Chan K, Zhao Q, Miao K, Luo K, Ge W, Xu X, Wang G, Liu T, Deng C. Accelerating precision anti-cancer therapy by time-lapse and label-free 3D tumor slice culture platform. Theranostics 2021, 11: 9415-9430. PMID: 34646378, PMCID: PMC8490519, DOI: 10.7150/thno.59533.Peer-Reviewed Original ResearchConceptsAnti-cancer therapyNew pre-clinical modelsDay of surgeryPre-clinical modelsRNA sequence analysisHigh-efficacy drugsAnti-cancer drug efficacyPD-1PD-L1Personalized medicineBlockade assayAnti-cancer drug discoveryImmune componentsOriginal tumorAutofluorescence featuresDrug efficacyHistological analysisPrecision anti-cancer therapyCancer treatmentDrug responseHigh-throughput drug screeningDrug discoveryTherapyEfficacyCell-based high-throughput drug screening
2020
Ethnic-specific BRCA1/2 variation within Asia population: evidence from over 78 000 cancer and 40 000 non-cancer cases of Indian, Chinese, Korean and Japanese populations
Bhaskaran S, Huang T, Rajendran B, Guo M, Luo J, Qin Z, Zhao B, Chian J, Li S, Wang S. Ethnic-specific BRCA1/2 variation within Asia population: evidence from over 78 000 cancer and 40 000 non-cancer cases of Indian, Chinese, Korean and Japanese populations. Journal Of Medical Genetics 2020, 58: 752-759. PMID: 32963034, DOI: 10.1136/jmedgenet-2020-107299.Peer-Reviewed Original ResearchNOTCH1 activation compensates BRCA1 deficiency and promotes triple-negative breast cancer formation
Miao K, Lei J, Valecha M, Zhang A, Xu J, Wang L, Lyu X, Chen S, Miao Z, Zhang X, Su S, Shao F, Rajendran B, Bao J, Zeng J, Sun H, Chen P, Tan K, Chen Q, Wong K, Xu X, Deng C. NOTCH1 activation compensates BRCA1 deficiency and promotes triple-negative breast cancer formation. Nature Communications 2020, 11: 3256. PMID: 32591500, PMCID: PMC7320176, DOI: 10.1038/s41467-020-16936-9.Peer-Reviewed Original ResearchMeSH KeywordsAllelesAnimalsAtaxia Telangiectasia Mutated ProteinsBRCA1 ProteinCarcinogenesisCell DeathCell Line, TumorCheckpoint Kinase 1Disease ProgressionDNA Transposable ElementsEpithelial-Mesenchymal TransitionFemaleGene Expression Regulation, NeoplasticHumansMice, KnockoutMitosisMutationReceptor, Notch1Signal TransductionTriple Negative Breast NeoplasmsConceptsTriple-negative breast cancerEpithelial-mesenchymal transitionHuman breast cancer tissuesBRCA1 mutation carriersBreast cancer tissuesBRCA1-deficient miceActivation of Notch1Breast cancer formationRefractory diseaseForm of Notch1Breast cancerMutation carriersHigh riskCancer tissuesClinical optionG2/M cell cycle checkpointFatal diseaseCell cycle checkpointsM cell cycle checkpointNotch1 activationBRCA1 deficiencyPhosphorylation of ATRNotch1Cancer formationCycle checkpoints
2017
Characterization of potential driver mutations involved in human breast cancer by computational approaches
Rajendran B, Deng C. Characterization of potential driver mutations involved in human breast cancer by computational approaches. Oncotarget 2017, 5: 50252-50272. PMID: 28477017, PMCID: PMC5564847, DOI: 10.18632/oncotarget.17225.Peer-Reviewed Original ResearchConceptsBreast cancerHuman breast cancerBreast cancer initiationForms of cancerPotential driver mutationsLethal cancersBreast tumorigenesisCancerDriver mutationsTumor initiationGenetic mutationsCancer initiationDriver genesPathway analysisProgressionMutation genesCellular regulatory pathwaysCandidate driversRegulatory pathwaysMetastasisCancer driversInitiation